Veeva Systems has announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China.
This announcement follows other big pharma names that have also recently committed to moving to Veeva Vault CRM, including GSK, Bayer, Boehringer Ingelheim and Novo Nordisk, along with many other smaller biopharma companies. More than 80 biopharmas are now live on Vault CRM.
Astellas is an existing Veeva customer expanding their partnership, with Astellas committing to moving off Veeva CRM (which is built on the Salesforce platform) and moving to Veeva Vault CRM (which is built on Veeva’s own Vault platform).
In 2023, Veeva announced the launch of Veeva Vault CRM, an evolved version of Veeva CRM, which now sits on its own Vault platform. In 2030, Veeva CRM will no longer be supported so biopharmas must migrate to a new platform before then. With Veeva Vault CRM, customers will be able to take advantage of Veeva’s new Veeva AI capabilities, which are not available in Veeva CRM.
“At Astellas, we discover and deliver transformative therapies for patients around the world,” said Nick Eshkenazi, Chief Digital and Transformation Officer at Astellas. “Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients.”
“Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions,” said Matt Farrell, President, Commercial Strategy at Veeva. “With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission.”
Vault CRM addresses the industry’s unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing and medical teams for seamless collaboration and more effective commercial execution.
